drugset / Trial / NCT06652243
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
Phase 0
Recruiting
12 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Celest Therapeutics (Shanghai) Co., Ltd. · collabSenti Biosciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3 (GPC3)-positive advanced hepatocellular carcinoma.
Timeline
- Start
- 2024-11-18
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | 5e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1e+09 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 2e+09 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |